Group 1 - The company has received approval from the National Medical Products Administration for clinical trials of Ketoprofen Gel Patch, which is intended for pain relief [1] - The product is classified as a Class 3 chemical drug and is indicated for conditions such as osteoarthritis, shoulder periarthritis, tendonitis, and muscle pain [1] - The Ketoprofen Gel Patch contains 30mg of Ketoprofen per 10g of gel and is administered topically, with a recommended dosage of one patch twice daily [1] Group 2 - Sales of Ketoprofen Gel Patch in China's major markets are projected to be approximately 49.58 million yuan in 2024 and about 76.44 million yuan in the first half of 2025 [2] - The approval for clinical trials is expected to enhance the company's product pipeline in the orthopedic chronic disease sector, potentially improving its strategic goals and core competitiveness [3] - The company acknowledges the long development cycle and high investment associated with drug research, which may introduce uncertainties regarding the approval and market performance of the product [3]

实丰文化发展股份有限公司董事会 2026年2月12日 实丰文化发展股份有限公司（以下简称"公司"、"实丰文化"或"上市公司"）于近日收到公司控股股东蔡 俊权先生之一致行动人蔡俊淞先生发来的《告知函》，蔡俊淞先生在2026年2月10日通过大宗交易方式 减持公司股份840,000股，占公司总股本的0.50%。根据有关法律法规和规范性文件的要求，现将具体情 况公告如下： ■ 特此公告。 登录新浪财经APP 搜索【信披】查看更多考评等级 股东蔡俊淞先生保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 ...

Group 1 - The core point of the article is that Huayin Securities has received notification from its controlling shareholder, Shenzhen Liyue Group, regarding the release of a portion of its pledged shares [1] - The announcement details the basic situation of the release of the pledged shares and the cumulative situation of the pledged shares held by the controlling shareholder [1] - As of the announcement date, there is no risk of forced liquidation or transfer of the pledged shares, indicating that the pledge risk is within a controllable range [1] Group 2 - The company will continue to monitor changes in the pledge situation and risks, fulfilling its information disclosure obligations in a timely manner [1] - Backup documents include the share release pledge registration certificate and details of share freezes from the China Securities Depository and Clearing Corporation [1]

Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. has approved a capital reduction and corresponding amendments to its articles of association, following the repurchase and cancellation of 3,000 restricted stocks from its 2022 incentive plan [1][2]. Group 1: Company Actions - The company held its fourth board meeting on September 17, 2025, and a temporary shareholders' meeting on November 24, 2025, to discuss the capital reduction [1]. - The company has completed the registration change for its capital reduction and received a new business license from the Harbin New Area Management Committee [1]. Group 2: Company Information - The registered capital of Harbin Sanlian Pharmaceutical is now RMB 316,354,550 [1]. - The company was established on June 21, 1996, and operates in various sectors including drug production, wholesale, retail, and import/export, as well as cosmetics and food production [1][2]. - The company is classified as a joint-stock company and is publicly listed [1].

Group 1 - The company received a written resignation letter from director Hu Min due to job relocation [2] - Hu Min's resignation will not result in the board having fewer members than the legal minimum, ensuring the normal operation of the board [2] - The resignation will take effect upon delivery to the board, and the company will proceed with the election of a new director according to legal procedures [2]

Core Viewpoint - The company, Shaanxi Zhongtian Rocket Technology Co., Ltd., has triggered the conditional redemption of its convertible bonds, "Tianjian Convertible Bonds," due to the stock price meeting specific criteria, leading to an early redemption scheduled for March 6, 2026 [4][11]. Group 1: Redemption Details - The redemption conditions for the convertible bonds are met as the company's stock price has been above 130% of the conversion price for at least 15 trading days within a 30-day period [4][11]. - The redemption price is set at 100.81 yuan per bond, which includes accrued interest at an annual rate of 1.50% [2][12]. - The redemption process includes a series of key dates: the last trading day is March 3, 2026, and the redemption registration date is March 5, 2026 [3][15]. Group 2: Bond Issuance and Trading - The company issued 4,950,000 convertible bonds on August 22, 2022, with a total value of 49.5 million yuan, and these bonds began trading on September 19, 2022 [5][4]. - The initial conversion price was set at 53.11 yuan per share, which has been adjusted multiple times due to dividend distributions [6][7][8]. Group 3: Conversion and Trading Procedures - The conversion period for the bonds lasts from six months after issuance until the maturity date [6][10]. - Holders of the convertible bonds must apply for conversion through the securities company that holds their bonds, with a minimum conversion unit of one bond [16].

Fundraising Overview - The company has successfully raised a total of RMB 706,999,968.84 through the issuance of 21,647,274 shares at a price of RMB 32.66 per share, with a net amount of RMB 692,070,721.95 after deducting issuance costs [1][2] - The funds have been deposited into a dedicated fundraising supervision account as of February 6, 2026, and have been verified by Tianjian Accounting Firm [1] Fund Management and Agreements - The company has established a special account for fundraising management, authorized by the third extraordinary shareholders' meeting in 2025, and has signed tripartite and quadripartite supervision agreements with relevant banks and the underwriter [2][4][5] - The tripartite agreement involves the company, China Construction Bank, Agricultural Bank of China, and the underwriter, while the quadripartite agreement includes the company, its subsidiary, and two additional banks [4][5] Fund Allocation and Usage - As of February 10, 2026, the balance in the special account at Jiaxing Bank is RMB 416,773,969.40, which includes RMB 196,273,969.40 for working capital and RMB 220,500,000.00 for the electronic-grade functional materials expansion project [3] - The company plans to use the funds for capital increase in its subsidiary, which will be subject to board approval before the transfer of funds [3] Regulatory Compliance - The agreements stipulate that the special account is exclusively for fundraising storage and usage, and both parties must comply with relevant laws and regulations [6] - The underwriter is responsible for supervising the use of funds and must conduct regular checks and audits [6][8]

Fundraising Overview - The company was approved to publicly issue 33,258,134 shares at a price of 21.96 RMB per share, raising approximately 730.35 million RMB, with a net amount of about 656.86 million RMB after deducting issuance costs [2] Change in Fund Usage - The company decided to change the use of part of the raised funds from a "100,000 tons/year multi-category plastic bottle high-quality recycling project" to a "5 million m² new decorative building materials project," reallocating 142.64 million RMB, which is 21.72% of the net amount raised [3][4] New Fund Management Agreements - The company established new special accounts for the raised funds and signed tripartite supervision agreements with its underwriter and banks to ensure compliance with regulations and protect investor interests [4][5][13] Special Account Details - As of February 9, 2026, the special account for the new project had a balance of approximately 22.64 million RMB, and the funds are strictly designated for the specified projects [5][13] Monitoring and Compliance - The underwriter is responsible for supervising the use of the raised funds, with provisions for regular audits and reporting to ensure adherence to the agreements [6][12][16] Reporting Obligations - The bank is required to provide monthly account statements to the company and the underwriter, ensuring transparency in fund management [11][16]

Group 1 - The company achieved an operating income of 483,815.26 million RMB in 2025, representing a year-on-year growth of 23.04% [2] - The net profit attributable to the parent company reached 93,503.03 million RMB, with a year-on-year increase of 45.89% [2] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 88,023.43 million RMB, showing a growth of 62.77% year-on-year [2] Group 2 - Total assets at the end of 2025 amounted to 725,222.49 million RMB, an increase of 14.98% compared to the beginning of the reporting period [2] - The equity attributable to the parent company was 386,925.38 million RMB, reflecting an 8.75% growth from the beginning of the reporting period [2] Group 3 - The company's performance was driven by embracing AI technologies, particularly in smart vehicle diagnostic terminals and smart energy hubs, which provided intelligent services to global customers [3] - In the smart charging sector, the company enhanced its end-to-end system capabilities, solidifying its position in various global industries [3][4] Group 4 - The significant growth in operating profit, total profit, and net profit attributable to the parent company was primarily due to improved profitability and operational efficiency [5] - The company's share capital increased significantly due to a rights issue in May 2025, where every 10 shares were converted into 4.9 additional shares [5] Group 5 - The company corrected its earnings forecast for 2025, with the net profit attributable to the parent company exceeding the upper limit of the previous forecast by 503.03 million RMB [7][8] - This adjustment was influenced by a court ruling that invalidated a patent dispute, allowing the company to reverse previously accrued liabilities of 24.79 million RMB [8]

登录新浪财经APP 搜索【信披】查看更多考评等级 公司简称：博瑞传播 证券代码：600880 编号：2026-004号 成都博瑞传播股份有限公司 公司将持续关注上述事项的进展情况，并按照相关法律法规的规定，及时履行相关信息披露义务。敬请 广大投资者理性投资，注意投资风险。 特此公告。 成都博瑞传播股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、本次无偿划转的基本情况 成都博瑞传播股份有限公司（以下简称"公司"）控股股东成都传媒集团拟将直接所持的公司股份 133,612,937股（占公司总股本的12.22%）及成都新闻实业有限责任公司（下称"新闻实业"）100%股权 无偿划转至其全资子公司成都传媒产业集团有限公司。本次无偿划转完成后，成都传媒产业集团将直接 取得公司12.22%股份，并通过取得新闻实业100%股权间接拥有公司23.37%的股份权益，合计持有公司 35.59%股份。公司实际控制人仍为成都市国有资产监督管理委员会。公司已于2025年10月30日、2026 年1月16日、2026年1月17日在上海证券 ...